To assess potential damage to HSPCs from the genetic modifying process, we first compared the fitness of mobilized peripheral blood CD34+ HSPCs from 2 HD and 6 XSCID patients following CRISPR-Cas9-AAV GE or lentiviral transduction. The gene discussed is CD34; the disease is T-B+ severe combined immunodeficiency due to gamma chain deficiency.